Medeor Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

Medeor Therapeutics General Information

Description

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve kidney transplant function and prevent graft rejection without currently available immunosuppressive (anti-rejection) drugs.

Contact Information

Formerly Known As
SERC Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medeor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Feb-2026 Completed Clinical Trials - Phase 3
6. Debt - PPP 29-Apr-2020 Completed Clinical Trials - Phase 3
5. Grant 22-Jan-2018 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 27-Nov-2017 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series A) 16-Oct-2015 Completed Clinical Trials - Phase 3
2. Early Stage VC 02-Oct-2013 $1.55M $2.55M Completed Clinical Trials - Phase 3
1. Seed Round 11-Jan-2013 $1M $1M Completed Clinical Trials - Phase 3
To view Medeor Therapeutics’s complete valuation and funding history, request access »

Medeor Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 1 1,291,667 $0.000100 8% $1.2 $1.2 1x $1.2 4.67%
Seed 1,000,000 $0.000100 8% $1 $1 1x $1 3.61%
To view Medeor Therapeutics’s complete cap table history, request access »

Medeor Therapeutics Patents

Medeor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240108655-A1 Methods of producing mixed chimerism after a solid organ transplant Pending 13-Sep-2022
US-20230201256-A1 Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient Inactive 21-May-2020
WO-2021236711-A1 Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient Inactive 21-May-2020
US-20220305057-A1 Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells Inactive 06-Jun-2019
EP-3980036-A1 Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells Inactive 06-Jun-2019 A61K35/28
To view Medeor Therapeutics’s complete patent history, request access »

Medeor Therapeutics FAQs

  • When was Medeor Therapeutics founded?

    Medeor Therapeutics was founded in 2012.

  • Where is Medeor Therapeutics headquartered?

    Medeor Therapeutics is headquartered in South San Francisco, CA.

  • What industry is Medeor Therapeutics in?

    Medeor Therapeutics’s primary industry is Drug Discovery.

  • Is Medeor Therapeutics a private or public company?

    Medeor Therapeutics is a Private company.

  • What is Medeor Therapeutics’s current revenue?

    The current revenue for Medeor Therapeutics is .

  • How much funding has Medeor Therapeutics raised over time?

    Medeor Therapeutics has raised $67.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process